» Articles » PMID: 38001692

Long-Term Follow-Up of Patients with Conjunctival Lymphoma After Individualized Lens-Sparing Electron Radiotherapy: Results from a Longitudinal Study

Abstract

Irradiation with electrons is the primary treatment regime for localized conjunctival low-grade lymphomas. However, radiation-induced cataracts are a major cause of treatment-related morbidity. This study investigates whether lens-sparing electron irradiation produces sufficient disease control rates while preventing cataract formation. All consecutive patients with strictly conjunctival, low-grade Ann Arbor stage IE lymphoma treated with superficial electron irradiation between 1999 and 2021 at our department were reviewed. A total of 56 patients with 65 treated eyes were enrolled with a median follow-up of 65 months. The median dose was 30.96 Gy. A lens-spearing technique featuring a hanging rod blocking the central beam axis was used in 89.2% of all cases. Cumulative incidences of 5- and 10-year infield recurrences were 4.3% and 14.6%, incidences of 5- and 10-year outfield progression were 10.4% and 13.4%. We used patients with involvement of retroorbital structures treated with whole-orbit photon irradiation without lens protection-of which we reported in a previous study-as a control group. The cumulative cataract incidence for patients treated with electrons and lens protection was significantly lower ( = 0.005) when compared to patients irradiated without lens protection. Thus, electrons are an effective treatment option for conjunctival low-grade lymphomas. The presented lens-sparing technique effectively prevents cataract formation.

References
1.
Hoskin P, Kirkwood A, Popova B, Smith P, Robinson M, Gallop-Evans E . 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014; 15(4):457-63. DOI: 10.1016/S1470-2045(14)70036-1. View

2.
Ferreri A, Sassone M, Miserocchi E, Govi S, Cecchetti C, Corti M . Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. Blood Adv. 2020; 4(6):1013-1019. PMC: 7094013. DOI: 10.1182/bloodadvances.2020001459. View

3.
McGrath L, Ryan D, Warrier S, Coupland S, Glasson W . Conjunctival Lymphoma. Eye (Lond). 2022; 37(5):837-848. PMC: 10049989. DOI: 10.1038/s41433-022-02176-2. View

4.
Jeon Y, Yang H, Choi B, Jung S, Park K, O J . Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma. EClinicalMedicine. 2019; 4-5:32-42. PMC: 6537565. DOI: 10.1016/j.eclinm.2018.10.001. View

5.
Yang X, Wang R, Yuan X, Yao S, Wang C, Cheng J . Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study. Radiat Oncol. 2022; 17(1):208. PMC: 9764465. DOI: 10.1186/s13014-022-02180-6. View